Revista de medicina de la Universidad de Navarra · 1997
[Intensive chemotherapy in the treatment of patients with metastatic breast cancer].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salgado J E, Aramendía J M, Fernández-Hidalgo O A, Lozano E, Rebollo J, Martínez-Monge R, Subirá M L, Brugarolas A
Аннотация
PURPOSE: Phase II study with intensive chemotherapy and autologous stem cells support in patients with metastatic breast cancer.
METHODS: Forty-nine patients were treated with high-doses of two cytotoxic drugs and support with stem cells obtained from several leukapheresis without movilitation. The cells were reinfused forty-eight hours after finishing the administration of chemotherapy.
RESULTS: Twenty-one patients (47%, CI-95%: 32.4-63.3%) achieved a complete remission. The objective responses rate was 73% (CI-95%: 57.2-85%). Overall and progression-free survival up to 4 years were 31% and 20%, respectively. Ten patients remain progression-free among 17 and 46 months. The most frequent extramedullary toxicity was hepatic and renal. Three patients (6%) died during the procedure.
CONCLUSIONS: Intensive chemotherapy with hematopoietic support yields, with a moderate toxicity, a high objective response and complete remission rate. A small group of patients achieves a long progression-free survival.
METHODS: Forty-nine patients were treated with high-doses of two cytotoxic drugs and support with stem cells obtained from several leukapheresis without movilitation. The cells were reinfused forty-eight hours after finishing the administration of chemotherapy.
RESULTS: Twenty-one patients (47%, CI-95%: 32.4-63.3%) achieved a complete remission. The objective responses rate was 73% (CI-95%: 57.2-85%). Overall and progression-free survival up to 4 years were 31% and 20%, respectively. Ten patients remain progression-free among 17 and 46 months. The most frequent extramedullary toxicity was hepatic and renal. Three patients (6%) died during the procedure.
CONCLUSIONS: Intensive chemotherapy with hematopoietic support yields, with a moderate toxicity, a high objective response and complete remission rate. A small group of patients achieves a long progression-free survival.
Предметные рубрики MeSH
Acute Kidney InjuryAdultAntineoplastic Combined Chemotherapy ProtocolsBone Marrow DiseasesBreast NeoplasmsCarboplatinCarcinoma, Ductal, BreastCombined Modality TherapyCyclophosphamideDisease ProgressionDisease-Free SurvivalEtoposideFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHepatic Veno-Occlusive DiseaseHumansLife TablesMiddle AgedMitoxantroneNeoplasm MetastasisNeoplasms, Hormone-DependentRadiotherapy, AdjuvantRemission InductionSalvage TherapySepsisShock, CardiogenicSurvival RateThiotepaTreatment Outcome